PROCEPT BioRobotics (PRCT) awards stock options and RSUs to EVP CTO Templin
Rhea-AI Filing Summary
PROCEPT BioRobotics Corp reported compensation-related equity awards to EVP and Chief Technology Officer Barry L. Templin. On August 13, 2026, he received a grant of 36,312 stock options with an exercise price of $21.95 per share, expiring on August 12, 2036. These options vest 1/48 monthly starting August 13, 2026, over four years, subject to continued service.
On the same date, he was also granted 26,246 restricted stock units (RSUs), each representing one share of common stock. One-quarter of the RSUs vest on August 13, 2027, with the remainder vesting quarterly over 36 months, contingent on continued service. Following the RSU grant, he directly holds 95,199 common shares. Both awards are intended to represent 50% of the value of his expected 2027 grant and are made in lieu of that portion.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 26,246 shares
Net Buy
2 txns
Insider
Templin Barry L
Role
EVP, Chief Technology Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 36,312 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 26,246 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 36,312 shares (Direct);
Common Stock — 95,199 shares (Direct)
Footnotes (2)
- F1. These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on August 13, 2027, with one-sixteenth of the remaining RSUs vesting quarterly over 36 months, subject to the Reporting Person continuing as a service provider through such date. The grant is intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant.
- F2. 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of August 13, 2026, over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date. The grant is intended to be 50% of the value of the Reporting Person's expected 2027 grant, and made in lieu of such portion of the expected 2027 grant.
Key Figures
Stock options granted: 36,312 options
Option exercise price: $21.95 per share
Option expiration: August 12, 2036
+5 more
8 metrics
Stock options granted
36,312 options
Grant to Barry L. Templin on August 13, 2026
Option exercise price
$21.95 per share
Exercise price of options expiring August 12, 2036
Option expiration
August 12, 2036
Expiration date of 36,312 stock options
RSUs granted
26,246 RSUs
Restricted stock units granted on August 13, 2026
Shares held after grant
95,199 shares
Direct common stock holdings following RSU grant
Initial RSU vesting date
August 13, 2027
One-quarter of RSUs vest on this date
Option vesting rate
1/48 monthly
Options vest monthly from August 13, 2026 over four years
Portion of expected 2027 grant value
50%
Both awards made in lieu of half of expected 2027 grant
Key Terms
restricted stock units (RSUs), vesting commencement date, Stock Option (Right to Buy), service provider
4 terms
restricted stock units (RSUs) financial
"These securities are restricted stock units (RSUs). Each RSU represents"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
vesting commencement date financial
"1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)"
service provider financial
"subject to the Reporting Person continuing as a service provider through such date"
FAQ
What equity awards did PROCEPT BioRobotics (PRCT) grant to Barry L. Templin?
Barry L. Templin received 36,312 stock options at $21.95 per share and 26,246 RSUs on August 13, 2026. The options vest monthly over four years and the RSUs vest over approximately four years, all subject to continued service.
How do the new RSUs for PROCEPT BioRobotics (PRCT) CTO vest?
The 26,246 RSUs vest with one-quarter on August 13, 2027, and the remaining three-quarters vesting quarterly over 36 months. Vesting requires Barry L. Templin to continue as a service provider through each applicable vesting date.
What is the vesting schedule for the new stock options at PROCEPT BioRobotics (PRCT)?
The 36,312 stock options granted to Barry L. Templin vest at 1/48 per month starting from the vesting commencement date of August 13, 2026. Vesting continues over four years, conditioned on his continued employment or service.
What is the exercise price and expiration of the new options at PROCEPT BioRobotics (PRCT)?
The new stock options have an exercise price of $21.95 per share and expire on August 12, 2036. These options provide the right to purchase common stock if vested and exercised before expiration, subject to plan terms.
How do these PROCEPT BioRobotics (PRCT) awards relate to Barry L. Templin’s 2027 grant?
Both the RSU and stock option grants are intended to be 50% of the value of Barry L. Templin’s expected 2027 grant. They are made in lieu of that portion of his anticipated 2027 equity compensation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
